Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
    • Podcast
  • Press Release
  • Media Coverage
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
    • Podcast
  • Press Release
  • Media Coverage
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Drug Shows Benefit in Metastatic Osteosarcoma
Clinical Breakthroughs

Drug Shows Benefit in Metastatic Osteosarcoma

By Anna WilliamsMay 23, 2019
Share
Facebook Twitter Email
Mark Agulnik, MD, professor of Medicine in the Division of Hematology and Oncology and medical director of the Clinical Trials Office at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, was a co-author of the study published in the Journal of Clinical Oncology.

A drug called regorafenib significantly improved progression-free survival in patients with metastatic osteosarcoma, according to the results of a clinical trial published in the Journal of Clinical Oncology.

“This exciting study showed that in a rare cancer with limited treatment options, new therapies can be discovered and improvements can be made in patient survival,” said co-author Mark Agulnik, MD, professor of Medicine in the Division of Hematology and Oncology and medical director of the Clinical Trials Office at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

Osteosarcoma is the most common type of bone cancer, and it tends to occur more frequently in children and adolescents. Patients are typically first treated with surgery and chemotherapy; but for those who experience relapse and metastasis, there are limited treatment options.

Previous research had suggested that regorafenib, an oral multikinase inhibitor, might provide a benefit in osteosarcoma.

The current trial, conducted through the Sarcoma Alliance for Research Through Collaboration (SARC), was designed to investigate whether regorafenib improved progression-free survival in patients with advanced osteosarcoma.

The multi-center phase II study enrolled 42 patients with progressive metastatic osteosarcoma who had all previously received at least one form of therapy. Participants were randomized to receive either regorafenib or a placebo.

Investigators found that progression-free survival among participants who received regorafenib was 3.6 months, compared to 1.7 months in the control group, and no new safety concerns were observed in the trial. Adverse events were considered manageable.

Regorafenib should therefore be considered a treatment option for patients with relapsed metastatic osteosarcoma, the authors concluded.

“For current patients without chemotherapy or clinical trial options, regorafenib is being prescribed based on the findings from this study,” Agulnik said.

In a separate phase II trial, Agulnik and collaborators through the Midwest Sarcoma Trials Partnership are also investigating the use of pazopanib and topotecan in patients with metastatic osteosarcoma who have experienced disease progression after chemotherapy.

The regorafenib clinical trial was supported in part by Bayer HealthCare Pharmaceuticals, which also provided regorafenib. Agulnik reported a past consulting or advisory role with Bayer.

Cancer Research
Share. Facebook Twitter Email

Related Posts

Hospitals Bound to Patient Safety Rules that Aren’t all Backed by Evidence

Jun 24, 2022

Identifying Protein Interactions that Promote Cancer Growth

Jun 24, 2022

Combination Treatment May Improve Quality of Life in Kidney Cancer

Jun 23, 2022

Comments are closed.

Latest News

Hospitals Bound to Patient Safety Rules that Aren’t all Backed by Evidence

Jun 24, 2022

Identifying Protein Interactions that Promote Cancer Growth

Jun 24, 2022

Combination Treatment May Improve Quality of Life in Kidney Cancer

Jun 23, 2022

Calcium Channel Blockers May Improve Chemotherapy Response

Jun 21, 2022

Expanded Role for Calcium Channels in T-Cells

Jun 17, 2022
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
20220607_Feinberg Campus_0070
20220607_Feinberg Campus_0066
20220607_Feinberg Campus_0054
Northwestern University 2022. Photo by Jim Prisching
20220607_Feinberg Campus_0077
20220607_Feinberg Campus_0063
20220607_Feinberg Campus_0111
20220607_Feinberg Campus_0083
20220607_Feinberg Campus_0018
20220607_Feinberg Campus_0023
20220607_Feinberg Campus_0072 (2)
20220607_Feinberg Campus_0120

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2022 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.